KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)Business Wire • 06/23/22
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor ProgramBusiness Wire • 06/08/22
KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare ConferenceBusiness Wire • 06/01/22
KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/11/22
KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental AllergyBusiness Wire • 03/22/22
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical TrialBusiness Wire • 03/07/22
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in PatientsBusiness Wire • 02/28/22
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/03/22
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022Business Wire • 02/02/22
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical ImmunologyBusiness Wire • 01/24/22
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary AngioedemaBusiness Wire • 11/10/21
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAEBusiness Wire • 11/08/21
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare ConferenceBusiness Wire • 09/21/21
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824Business Wire • 09/14/21
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary AngioedemaBusiness Wire • 08/23/21
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAEBusiness Wire • 07/12/21
Analysts Estimate KalVista Pharmaceuticals, Inc. (KALV) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 06/30/21
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)Business Wire • 06/28/21
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema WorkshopBusiness Wire • 06/05/21
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/27/21
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema WorkshopBusiness Wire • 05/10/21